Inventors:
James Arnold - San Francisco CA, US
Phil Edwards - Kennett Square PA, US
Mark Sylvester - Waltham MA, US
Stefan Berg - Sodertalje, SE
Jörg Holenz - Sodertalje, SE
Annika Kers - Sodertalje, SE
Karin Kolmodin - Sodertalje, SE
Laszlo Rakos - Sodertalje, SE
Liselotte Öhberg - Sodertalje, SE
Rotticci Didier - Sodertalje, SE
Gianni Chessari - Cambridge, GB
Miles Congreve - Cambridge, GB
Christopher Murray - Cambridge, GB
Sahil Patel - Cambridge, GB
Assignee:
ASTRAZENECA AB - Sodertalje
ASTEX THERAPEUTICS LTD. - Cambridge
International Classification:
A61K 31/4035
C07D 209/44
C07D 401/10
C07D 403/10
C07D 405/12
C07D 401/14
C07D 403/04
C07D 403/14
C07D 417/14
A61K 31/4439
A61K 31/506
A61K 31/444
A61P 25/00
A61P 25/28
A61P 9/00
C12N 9/99
US Classification:
514256, 548471, 5462771, 544333, 548454, 546256, 5462754, 544316, 544296, 5462701, 514416, 514339, 514414, 514333, 514274, 514338, 435184
Abstract:
This invention relates to novel compounds having the structural formula I below:and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.